MedTrace Logo

The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy

NCT02315235 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-04-15

No results posted yet for this study

Summary

To investigate the efficacy and safety of autologous peripheral blood stem cell based therapy in patients with diabetic painful neuropathy.

Conditions

  • Diabetic Neuropathy

Interventions

BIOLOGICAL

Normal saline

Normal saline is injected in one leg of patient.

BIOLOGICAL

stem-cell

Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day. The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hye Seung Jung, Ph.D. · Seoul Nation University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315235 on ClinicalTrials.gov